One-Shot gene therapy trial aims to turn body into Cancer-Fighting factory
NCT ID NCT07192432
Summary
This first-in-human trial is testing a new gene therapy called VNX-202 for people with HER2-positive cancers. The therapy uses a single IV infusion to teach the liver to continuously produce cancer-fighting proteins, potentially eliminating the need for repeated treatments. Researchers will first find the safest dose in patients with advanced cancer, then test it in people with early-stage cancer at high risk of recurrence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-EXPRESSING SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SCRI Denver DDU at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.